Pasithea Therapeutics Corp.
KTTA evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $17.7M
- Lead Asset:
- pas-004 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for KTTA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KTTA
Pasithea Therapeutics Corp. (KTTA) is a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor, for RASopathies, MAPK pathway-driven tumors, and CNS disorders [sec_mda · as of 2026-08-14].
Key risk: Early-stage pipeline
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for Pasithea Therapeutics Corp..
Pasithea Therapeutics Corp. (KTTA) is a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor, for RASopathies, MAPK pathway-driven tumors, and CNS disorders [sec_mda · as of 2026-08-14].
- Lead candidate PAS-004 is a next-generation oral once-daily macrocyclic MEK inhibitor [sec_mda · as of 2026-08-14].
- Cash & equivalents of $45.7M as of 2026-06-30; net income -$5.3M; shareholders' equity $49.8M [sec].
- Phase 1/1b trials ongoing for MAPK pathway-driven advanced solid tumors (started 2024-02-29) and for neurofibromatosis type 1 (NF1) plexiform neurofibromas (started 2025-05-30) [catalyst].
- Closed a $60M public offering in December 2025, extending cash runway through at least the first half of 2028 [news · published 2025-12-02].
- Interim safety and activity data for PAS-004 in solid tumors reported in June 2026; further early results expected in November 2026 [news · published 2026-06-30][news · published 2026-09-14].
What works
- PAS-004 is a next-generation macrocyclic MEK inhibitor designed to address limitations of existing MEK inhibitors, potentially offering improved pharmacokinetics and tolerability [sec_mda · as of 2026-08-14].
- The company has a substantial cash position of $45.7M as of 2026-06-30, bolstered by a $60M public offering in late 2025, providing runway through at least the first half of 2028 [sec][news · published 2025-12-02].
- Two Phase 1/1b clinical trials are actively enrolling, covering both advanced solid tumors and NF1-associated plexiform neurofibromas, diversifying the pipeline [catalyst].
What to weigh
- The company is pre-revenue and reported a net loss of $5.3M for the period ending 2026-06-30, reflecting the high cost of clinical-stage R&D [sec].
- PAS-004 is still in early Phase 1/1b trials; no pivotal efficacy data have been released, and the solid tumor trial is not expected to complete until 2028 [sec_mda · as of 2026-03-30].
- Several prior subsidiaries (U.K., Portugal, Clinics) have been dissolved, indicating past restructuring and discontinuation of operations [sec_mda · as of 2026-03-30].
From the filings
Quoted directly from source documents.
PAS-004 is a next-generation oral once-daily macrocyclic MEK inhibitor for RASopathies, MAPK pathway-driven tumors, and CNS disorders.
“We are a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for RASopathies, MAPK pathway-driven tumors and other diseases, including central nervous system (CNS) disorders. Our lead product candidate, PAS-004, is a next-generation oral once-daily macrocyclic mitogen-activated protein kinase, or MEK inhibitor”
SEC MD&A · August 14, 2026
Phase 1/1b trial for NF1 plexiform neurofibromas started in May 2025.
“Phase1_Start: A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas”
Catalysts · May 30, 2025
Catalyst timeline
- 2024-02-29 · Phase 1 start for PAS-004 in MAPK pathway-driven advanced solid tumors — First patient dosed in the Phase 1 open-label study assessing safety, tolerability, PK, and PD of PAS-004 in patients with RAS, NF1, or RAF mutations or who have failed BRAF/MEK inhibition.
- 2025-05-30 · Phase 1/1b start for PAS-004 in NF1 plexiform neurofibromas — Initiation of a Phase 1/1b open-label study in adult participants with NF1 and symptomatic, inoperable, incompletely resected, or recurrent plexiform neurofibromas.
Risks & what to watch (3)›
Key risks
- Early-stage pipeline — PAS-004 is in Phase 1/1b; no pivotal data yet, and solid tumor trial completion expected in 2028 [sec_mda · as of 2026-03-30].
- Pre-revenue with net losses — Company reported net loss of $5.3M for period ending 2026-06-30, typical for clinical-stage biotech [sec].
- Past subsidiary dissolutions — Several subsidiaries (U.K., Portugal, Clinics) have been dissolved, indicating restructuring [sec_mda · as of 2026-03-30].
What to watch
- November 2026 early PAS-004 clinical trial results from the NF1 and solid tumor studies [news · published 2026-09-14].
- Protocol amendment to continue dose escalation in the solid tumor trial using tablet formulation [sec_mda · as of 2026-03-30].
- Initiation of a Phase 1 trial for pediatric NF1 patients, as indicated in the company's development plan [sec_mda · as of 2026-05-15].
- Cash runway management: $45.7M as of 2026-06-30, with guidance that funds extend through at least first half of 2028 [sec][news · published 2025-12-02].
Sources: Catalysts · News · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Pasithea Therapeutics Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pasithea Therapeutics Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.04 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$9.5M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 2,100,000 | $1.6M |
| adage capital partners gp, l.l.c. | 2,100,000 | $1.6M |
| squadron capital management llc | 2,100,000 | $1.6M |
| vivo capital, llc | 2,100,000 | $1.6M |
| ameriprise financial inc | 1,350,896 | $1.0M |
| cable car capital, lp | 1,206,379 | $895K |
| stonepine capital management, llc | 831,301 | $617K |
| advisorshares investments llc | 337,508 | $250K |
| persistent asset partners ltd | 290,555 | $216K |
| geode capital management, llc | 103,985 | $77K |
Showing top 10 of 21 institutional holders of Pasithea Therapeutics Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 1.1%
- Days to cover
- 0.3
- Shares short
- 267,043
- Daily short volume (Oct 12, 2026)
- 4.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KTTA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Pasithea Therapeutics Corp.?
Pasithea Therapeutics Corp. (KTTA) is a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor, for RASopathies, MAPK pathway-driven tumors, and CNS disorders [sec_mda · as of 2026-08-14].
What is Pasithea Therapeutics Corp.'s lead drug candidate?
Pasithea Therapeutics Corp.'s most advanced tracked candidate is pas-004 (Phase 1) for RAS Mutation; NF1 Mutation.
Who is the CEO of Pasithea Therapeutics Corp.?
Dr. Tiago Reis Marques M.D., Ph.D. is the chief executive officer of Pasithea Therapeutics Corp. (KTTA).
Where is Pasithea Therapeutics Corp. headquartered?
Pasithea Therapeutics Corp. (KTTA) is headquartered in Miami Beach, FL, United States.
What therapeutic areas does Pasithea Therapeutics Corp. focus on?
Pasithea Therapeutics Corp. develops therapies across Oncology, Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.